VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

Igor Aurer, MD
Published: Tuesday, Jul 26, 2016


Igor Aurer, MD, Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Croatia, discusses new treatment approaches in Hodgkin lymphoma.
 
The approval of brentuximab vedotin for Hodgkin lymphoma was significant and there is now mature data that further confirms its longterm benefit, said Aurer. It is being investigated in combination with other agents and seems to be active without any increase in toxicity.
 
Another class of agents that has been shown to be very active and very tolerable in Hodgkin lymphoma is checkpoint inhibitors, said Aurer.
 
PD-1 blockers have the potential to restore immunological sensitivity to Hodgkin lymphoma and enable host T-cells to attack and destroy tumor cells. We will still need to wait longer to get data regarding combination in this setting, said Aurer.
 

Igor Aurer, MD, Division of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb, Croatia, discusses new treatment approaches in Hodgkin lymphoma.
 
The approval of brentuximab vedotin for Hodgkin lymphoma was significant and there is now mature data that further confirms its longterm benefit, said Aurer. It is being investigated in combination with other agents and seems to be active without any increase in toxicity.
 
Another class of agents that has been shown to be very active and very tolerable in Hodgkin lymphoma is checkpoint inhibitors, said Aurer.
 
PD-1 blockers have the potential to restore immunological sensitivity to Hodgkin lymphoma and enable host T-cells to attack and destroy tumor cells. We will still need to wait longer to get data regarding combination in this setting, said Aurer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x